Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Approval Obtained for Initiating Clinical Trials for Dulaglutide Injection (BA5101) in the U.S.

Placing of New Shares under General Mandate

First in China: Boan Biotech’s Novel Investigational CD228-Directed ADC Approved for Clinical Trials

Yantai, July 25, 2024 – Boan Biotech today announced that its investigational drug candidate, a novel CD228-directed antibody drug conjugate (ADC) for injection codenamed BA1302, has been approv...

Approval Obtained for Initiating Clinical Trial for the Novel ADC Candidate BA1302 in China

Positive Profit Alert

BLA for Boan Biotech’s BA9101 (Aflibercept) Accepted in China

Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for the com...

Acceptance of BLA in China for Aflibercept Intravitreous Injection (BA9101)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024